Biocon is introducing Bosaya (denosumab-kyqq), a biosimilar to Prolia, and Aukelso (denosumab-kyqq), a biosimilar to Xgeva.

Apotex Inc. ("Apotex" or the "Company"), the largest Canadian‑based global pharmaceutical company, today announced that Health Canada has approved DENOZA™ (denosumab injection), a biosimilar ...

Biocon announced the launch of Bosaya™ and Aukelso™ (denosumab-kyqq) in the U.S. and available by prescription nationwide.

Bosaya(TM) and Aukelso(TM) (both denosumab-kyqq products) now available in the United States, following U.S. FDA approval in September 2025 with an interchangeable designation -- Potential benefit to ...

Biocon makes US commercial launch of Bosaya and Aukelso, denosumab biosimilars: Our Bureau, Bengaluru Wednesday, April 8, 2026, 16:10 Hrs [IST] Biocon has made a commercial launch ...

Biocon launches two FDA-approved interchangeable denosumab biosimilars in the US, targeting osteoporosis and bone metastasis in a $5B market.

Biocon Limited has announced the commercial launch of its denosumab biosimilars, Bosaya and Aukelso, in the United States, ...

Potential benefit to the estimated 10 million adults with osteoporosis and over 330,000 patients annually with bone ...

Amgen (AMGN) stock climbs as MariTide GLP-1 trials demonstrate nearly 20% weight loss. Truist raises price target to $325 ...

New Delhi, Apr 7 (PTI) Biocon Ltd on Tuesday announced the commercial launch of biosimilars Bosaya and Aukelso, indicated for different serious bone conditions, in the US.Bosaya (biosimilar to Prolia) ...

Alongside the approval of Ponlimsi, the FDA is reviewing a BLA for TEV-45779, a biosimilar candidate for Xolair, covering all currently approved indications.